1-9 of 9
Sandra J. Horning, M.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).

Thomas E. Witzig, MD, Fangxin Hong, Ph.D., Ivana N. Micallef, MD, Randy D. Gascoyne, MD, Ahmet Dogan, MD, PhD, Henry Wagner, Jr., MD, Ranjana H. Advani, MD, Brad S. Kahl, M.D., Sandra J. Horning, M.D.
Journal: Blood
Blood (2012) 120 (21): 2687.
https://doi.org/10.1182/blood.V120.21.2687.2687
Published: 2012
Journal Articles

Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma

Lynne I. Wagner, Ph.D., Fengmin Zhao, Ph.D., Michael E. Williams, M.D., Randy D. Gascoyne, MD, John C. Krauss, M.D., David Cella, Ph.D., Sandra J. Horning, M.D., Brad S. Kahl, M.D.
Journal: Blood
Blood (2012) 120 (21): 235.
https://doi.org/10.1182/blood.V120.21.235.235
Published: 2012
Journal Articles

Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma

Brad S. Kahl, M.D., Hailun Li, MS, Mitchell R Smith, MD, PhD, Randy D. Gascoyne, MD, David T. Yang, MD, Elisabeth Paietta, PhD, Ranjana H. Advani, MD, Sandra J. Horning, M.D.
Journal: Blood
Blood (2012) 120 (21): 153.
https://doi.org/10.1182/blood.V120.21.153.153
Published: 2012
Journal Articles

Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years

Ranjana H. Advani, MD, Hailun Li, MS, Richard T. Hoppe, MD, Nancy L. Bartlett, MD, John M. Bennett, MD, Donna S. Neuberg, ScD, Peter A Cassileth, MD, Brad S. Kahl, M.D., Sandra J. Horning, M.D.
Journal: Blood
Blood (2012) 120 (21): 4779.
https://doi.org/10.1182/blood.V120.21.4779.4779
Published: 2012
Journal Articles

Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)

Lode J. Swinnen, Hailun Li, MS, Andrew Quon, MD, Randy D. Gascoyne, MD, Erik A. Ranheim, MD, Thomas M Habermann, MD, Ranjana H. Advani, MD, Brad S. Kahl, M.D., Sandra J. Horning, M.D.
Journal: Blood
Blood (2012) 120 (21): 687.
https://doi.org/10.1182/blood.V120.21.687.687
Published: 2012
Journal Articles

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant

Meghan S. Karuturi, MD, Sally Arai, MD, Robert W. Chen, MD, Ajay K. Gopal, MD, Lei Feng, Ying Yuan, Ph.D, Scott E. Smith, MD, PhD, Stephen M. Ansell, M.D., Ph.D., Joseph D Rosenblatt, MD, Kerry J. Savage, MD MSc, Radhakrishnan Ramchandren, MD, Nancy L Bartlet, Bruce D. Cheson, MD, Andres Forero-Torres, MD, Craig H. Moskowitz, MD, Joseph M. Connors, MD, Michelle A. Fanale, MD, Sven de Vos, MD, PhD, Andreas Engert, MD, Tim Illidge, PhD, Peter Borchmann, MD, Franck Morschhauser, MD, PhD, Sandra J. Horning, M.D., Anas Younes, MD
Journal: Blood
Blood (2012) 120 (21): 3701.
https://doi.org/10.1182/blood.V120.21.3701.3701
Published: 2012
Journal Articles

Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab

Thomas M Habermann, MD, Fangxin Hong, PhD, Vicki A. Morrison, MD, Shaker R. Dakhil, MD, James K. Weick, MD, Stanley R. Frankel, MD, Randy D. Gascoyne, MD, Richard I Fisher, MD, Bruce D. Cheson, MD, Edie A. Weller, PhD, Brad S. Kahl, M.D., Bruce A. Peterson, MD, Howard S Hochster, MD, Sandra J. Horning, M.D.
Journal: Blood
Blood (2012) 120 (21): 3705.
https://doi.org/10.1182/blood.V120.21.3705.3705
Published: 2012
Journal Articles

Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Annette E. Hay, MBChB, Beate Klimm, MD, Bingshu E. Chen, PhD, Helen Goergen, Lois E. Shepherd, M.D., Michael Fuchs, MD, Mary Gospodarowicz, MD, Peter Borchmann, MD, Joseph M. Connors, MD, Jana Markova, MD, Michael Crump, MD, FRCPC, Andreas Lohri, MD, Jane N. Winter, MD, Bernd Dörken, Robert G. Pearcey, MD, Volker Diehl, MD, Sandra J. Horning, M.D., Hans Theodor Eich, MD, Andreas Engert, MD, Ralph M. Meyer, MD
Journal: Blood
Blood (2012) 120 (21): 548.
https://doi.org/10.1182/blood.V120.21.548.548
Published: 2012
Journal Articles

Mature Results of a Prospective Trial of Rituximab in Patients (Pt) with Post Transplant Lymphoproliferative Disorder (PTLD) Unresponsive or Ineligible for Reduced Immunosuppression (RIS).

Jeff P. Sharman, MD, Donald E. Tsai, M.D., Clare J. Twist, M.D., Steven M. Horwitz, M.D., Carol D. Jones, M.D., Sandra J. Horning, M.D.
Journal: Blood
Blood (2006) 108 (11): 2755.
https://doi.org/10.1182/blood.V108.11.2755.2755
Published: 2006